28.27
-8.78 (-23.70%)
| Previous Close | 37.05 |
| Volume | 3,438,845 |
| Price / Sales | 4.43 |
| Price / Book | 115.92 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,921.38% |
| Diluted EPS (TTM) | -0.640 |
| Quarterly Revenue Growth (YOY) | -75.50% |
| Total Debt/Equity (MRQ) | 108.28% |
| Current Ratio (MRQ) | 1.03 |
| Operating Cash Flow (TTM) | -34.72 M |
| Levered Free Cash Flow (TTM) | -18.34 M |
| Return on Assets (TTM) | -67.62% |
| Return on Equity (TTM) | -221.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Cue Biopharma, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.21 |
|
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.35% |
| % Held by Institutions | 19.45% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ikarian Capital, Llc | 30 Jun 2026 | 104,364 |
| Tetragon Partners Gp Ltd | 30 Jun 2026 | 93,819 |
| Stempoint Capital Lp | 30 Jun 2026 | 66,995 |
| Adar1 Capital Management, Llc | 30 Jun 2026 | 55,193 |
| Lion Point Capital, Lp | 30 Jun 2026 | 52,928 |
| Squadron Capital Management Llc | 30 Jun 2026 | 50,000 |
| Boothbay Fund Management, Llc | 30 Jun 2026 | 31,459 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |